Drugs / CAR-NK-CD19
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05410041 | May 2022 → Apr 2023 | B-cell chronic lymphocytic leukemia | Beijing Boren Hospital | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CAR-NK-CD19 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05410041 ↗ |
| Modality | Cell therapy | “Anti-CD19 CAR-Engineered NK Cells” NCT05410041 ↗ |
| Target | CD19 | “Anti-CD19 CAR-Engineered NK Cells” NCT05410041 ↗ |